Mr. Alejandro Antalich reports

BIOMIND LABS ANNOUNCES RESULTS OF ANNUAL GENERAL & SPECIAL MEETING

Biomind Labs Inc. has released the voting results from its annual general and special meeting of shareholders held in Vancouver, B.C., on Feb. 4, 2026. A total of 48,170,817 common shares of the company were voted, representing 62.10 per cent of the total common shares issued and outstanding as at the record date of the meeting. Shareholders voted in favour of all matters brought before them at the meeting, which matters are discussed in detail in the company's management information circular dated Jan. 2, 2026, that is available on SEDAR+.

As a result:

• Davidson & Co. LLP, chartered professional accountants, was reappointed as auditor of the company (48,170,817 shares (100.00 per cent) voted in favour).
• The number of directors was set at five with the following nominees elected as directors: Alejandro Antalich, Oscar Leon, Ravi Sood, Ben Illigens and Scott Ackerman (48,170,817 shares (100.00 per cent) voted in favour).
• The company's rolling stock option plan was reapproved (48,170,756 shares (99.99 per cent) voted in favour, 61 shares (0.01 per cent) voted against).

The following officers were reappointed after the meeting: Mr. Antalich as chief executive officer and Mr. Leon as chief financial officer and corporate secretary.

About Biomind Labs Inc.

Biomind Labs is a clinical-stage biopharmaceutical company focused on transforming breakthroughs in neuroscience and biomedical research into novel pharmaceutical drugs and proprietary nanotechnology-based delivery systems for psychiatric and neurological conditions that affect the central nervous system. Leveraging translational neuroscience and formulation science, Biomind aims to optimize the pharmacological profile of key endogenous and naturally derived molecules to address unmet needs in CNS therapeutics. The company is committed to rigorous clinical validation and patient-centric innovation.

We seek Safe Harbor.